natgillin/translations-raw huggingface dataset:
a heat exchanger for recovering the heat of the gaseous current leaving the catalytic-bed reactor; and a condensation apparatus for separating the water from the gaseous current leaving the heat exchanger. 
izmjenjivač topline za preuzimanje topline iz struje plina koja izlazi iz reaktora s katalitičkim slojem; i kondenzator za izdvajanje vode iz struje plina koja izlazi iz izmjenjivača topline.
The plant for treating waste waters of olive oil mills as per Claim 12, characterized in that, when the catalytic-bed reactor is replaced by a membrane reactor, said plant comprises: a station for filtering the waste waters for removal of the fixed residue; 
Postrojenje za obradu otpadnih voda iz mlinova za maslinovo ulje u skladu s patentnim zahtjevom 12, naznačeno time što, kada se reaktor s katalitičkim slojem zamijeni membranskim reaktorom, navedeno postrojenje sadrži: stanicu za filtriranje otpadnih voda radi uklanjanja čvrstog ostatka;
an apparatus for concentration of the waste waters, once filtered, in order to obtain an aqueous solution with concentrated organic fraction usable as supply current; 
uređaj za koncentriranje otpadnih voda, nakon filtriranja, kako bi se dobilo vodenu otopinu s koncentriranom organskom frakcijom koju se može upotrijebiti kao dovodnu struju;
a device for vaporizing said supply current; 
napravu za isparavanje navedene dovodne struje;
a heat exchanger for recovering the heat of the hydrogen-free gaseous current leaving the membrane reactor; and a condensation apparatus for separating the water from the gaseous current leaving the heat exchanger. 
izmjenjivač topline za preuzimanje topline iz struje plina koja ne sadrži vodik i izlazi iz membranskog reaktora; i kondenzator za izdvajanje vode iz struje plina koja izlazi iz izmjenjivača topline.
The plant for treating waste waters of olive oil mills as per Claim 12, characterized in that, in the case where the reforming of methane takes place in the catalytic-bed reactor, means are provided to send the waste waters directly to the reformer after the filtering station. 
Postrojenje za obradu otpadnih voda iz mlinova za maslinovo ulje u skladu s patentnim zahtjevom 12, naznačeno time što, u slučaju kada se reformiranje metana provodi u reaktoru s katalitičkim slojem, osiguran je način za slanje otpadnih voda izravno u reformator nakon filtracijske stanice.
A non-therapeutic method of generating an antibody, comprising administering to an animal which is a rat, a hamster, a rabbit or a mouse a polypeptide according to claim 2. 
Neterapijski postupak stvaranja protutijela, naznačen time, da se sastoji od primjene polipeptida iz patentnog zahtjeva 2 na životinju koja je štakor, hrčak, zec ili miš.
A monoclonal antibody that binds to the polypeptide of claim 2; binds to human sclerostin with a dissociation constant of less than or equal to 1 x 10-9 M as determined by surface plasmon resonance; and increases at least one of bone formation, bone mineral density, bone mineral content, bone mass, bone quality and bone strength in a mammal. 
Monoklonsko protutijelo koje se veže za polipeptid iz patentnog zahtjeva 2, naznačen time, da se veže za humani sklerostin s disocijacijskom konstantom manjom ili jednakom od 1 x 10-9 M kako je izmjereno površinskom plazmonskom rezonancijom; te povećava barem jednu formaciju kosti, mineralnu gustoću kosti, mineralni sastav kosti, koštanu masu, kvalitetu kosti i jačinu kosti kod sisavca.
A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1-12 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 12, i farmaceutski prihvatljiv nosač.
The pharmaceutical composition of claim 13, wherein the compound of Formula (I) is bound to an aluminum-containing adjuvant. 
Farmaceutski sastav prema zahtjevu 13, naznačen time, da je spoj formule (I) vezan na pomoćno sredstvo koje sadrži aluminij.
The pharmaceutical composition of claim 14, wherein the aluminum-containing adjuvant is selected from aluminum hydroxide, aluminum oxyhydroxide and aluminum hydroxyphosphate. 
Farmaceutski sastav prema zahtjevu 14, naznačen time, da je pomoćno sredstvo koje sadrži aluminij, odabrano između aluminijevog hidroksida, aluminijevog oksihidroksida i aluminijevog hidroksifosfata.
The compound for use in a method of treatment of claim 17, wherein the disease or condition is an infectious disease, an inflammatory disease, a respiratory disease, a dermatological disease or an autoimmune disease. 
Spoj za uporabu u postupku liječenja prema zahtjevu 17, naznačen time, da se kod bolesti ili poremećaja radi o sljedećem stanju: infektivna bolest, upalna bolest, respiratorna bolest, dermatološka bolest ili autoimuna bolest.
The compound for use in a method of treatment of claim 17, wherein the disease or condition is asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), ulcerative colitis, Crohns disease, bronchitis, dermatitis, actinic keratosis, basal cell carcinoma, allergic rhinitis, psoriasis, scleroderma, urticaria, rheumatoid arthritis, multiple sclerosis, cancer, breast cancer, HIV or lupus. 
Spoj za uporabu u postupku liječenja prema zahtjevu 17, naznačen time, da su bolest ili stanje sljedeći: astma, kronična opstrukcijska plućna bolest (COPD), sindrom respiratornog poremećaja kod odraslih (ARDS), ulcerativni kolitis, Crohnova bolest, bronhitis, dermatitis, aktinijska keratoza, karcinom bazalnih stanica, alergijski rinitis, psorijaza, skleroderma, urtikarija, reumatoidni artritis, multipla skleroza, rak, rak dojke, HIV ili lupus.
The use of claim 20, wherein the disease or condition is an infectious disease, an inflammatory disease, a respiratory disease, a dermatological disease or an autoimmune disease. 
Uporaba prema zahtjevu 20, naznačena time, da se kod bolesti ili poremećaja radi o sljedećem stanju: infektivna bolest, upalna bolest, respiratorna bolest, dermatološka bolest ili autoimuna bolest.
The use of claim 20 wherein the disease or condition is asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), ulcerative colitis, Crohns disease, bronchitis, dermatitis, actinic keratosis, basal cell carcinoma, allergic rhinitis, psoriasis, scleroderma, urticaria, rheumatoid arthritis, multiple sclerosis, cancer, breast cancer, HIV or lupus. 
Uporaba prema zahtjevu 20, naznačena time, da su bolest ili stanje sljedeći: astma, kronična opstrukcijska plućna bolest (COPD), sindrom respiratornog poremećaja kod odraslih (ARDS), ulcerativni kolitis, Crohnova bolest, bronhitis, dermatitis, aktinijska keratoza, karcinom bazalnih stanica, alergijski rinitis, psorijaza, skleroderma, urtikarija, reumatoidni artritis, multipla skleroza, rak, rak dojke, HIV ili lupus.
Glass container package according claim 1, wherein the thread turns (7) extend over a height (h3) of between 5 mm and 20 mm. 
Stakleni spremnik kao ambalaža u skladu s patentnim zahtjevom 1, naznačen time što se zakreti navoja (7) pružaju po visini (h3) od između 5 mm i 20 mm.
Glass container package according to one of the preceding claims, wherein the straight cylindrical section (51) has an internal diameter (d1) defined by the internal wall (5), wherein the internal diameter (d1) is selected within an interval of 18 mm to 21 mm. 
Stakleni spremnik kao ambalaža u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što ravni valjkasti dio (51) ima unutarnji promjer (d1) omeđen unutarnjom stijenkom (5), gdje se unutarnji promjer (d1) bira u intervalu od 18 mm do 21 mm.
Glass container package according to one of the preceding claims, wherein the thread turns (7) of the internal thread (6) are identical and distributed at regular angular intervals over the internal wall (5) of the neck (1). 
Stakleni spremnik kao ambalaža u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što su zakreti navoja (7) unutarnjeg navoja (6) isti i raspoređeni po pravilnim kutnim razmacima po unutarnjoj stijenci (5) grla (1).
A method for the continuous alkylation of cyclic tertiary amines comprising: 
Postupak za kontinuiranu alkilaciju ciklličnih tercijarnih amina koji sadrži:
maintaining the temperature within the range of 20-200°C; 
održavanje temperature unutar opsega od 20-200°C;
isolating the pure quaternary cyclic ammonium compound; wherein said cyclic tertiary amines and quaternary cyclic quaternary ammonium compounds are compounds of general formula respectively, wherein R is a linear or branched C1-C12 alkyl group; 
izolaciju čistog kvaternarnog cikličkog amonijskog spoja, pri čemu, navedeni ciklički tercijarni amini i kvaternarna ciklički amonijski spojevi su spojevi opće formule [image] respektivno, gdje R je linearna ili granata C1-C12 alkil skupina;
X is a halogen atom or a carbonate, sulfate or triflate; 
X je atom halogena ili karbonat, sulfat ili triflat;
A method according to claim 1 wherein R is a C1-C4 alkyl group. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što R je C1-C4 alkil skupina.
A method according to claim 2 wherein R is methyl or isopropyl. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što R je metil ili izopropil.
A method according to claim 6 wherein Y is a group of formula: wherein R2, R3 and R4, the same or different, are hydrogen, hydroxy, hydroxyalkyl, preferably hydroxymethyl, phenyl, cycloalkyl, preferably cyclopentyl, and heteroaryl, preferably thienyl. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što Y je skupina formule: [image] gdje R2, R3 i R4, isti ili različiti, su vodik, hidroksi, hidroksialkil, poželjno hidroksimetil, fenil, cikloalkil, poželjno ciklopentil, i heteroaril, poželjno tienil.
A method according to claim 1 wherein the alkylating agent is a compound of formula R1X wherein R1 and X have the above reported meanings. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je alkalno sredstvo spoj formule R1X gde R1 i X imaju gore navedena značenja.
A method according to claim 9 wherein the alkylating agent is selected among methyl chloride, methyl bromide, methyl iodide, ethyl chloride, ethyl bromide, ethyl iodide, n-propyl chloride, n-propyl bromide, n-propyl iodide, isopropyl chloride, isopropyl bromide, and isopropyl iodide. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što je alkalno sredstvo odabrano iz metil klorida, metil bromida, metil jodida, etil klorida, etil bromida, etil jodida, n-propil klorida, n-propil bromida, n-propil jodida, izopropil klorida, izopropil bromida i izopropil jodida.
A method according to claim 10 wherein the alkylating agent is methyl bromide. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time što alkalno sredstvo je metil bromid.
A method according to claim 1 wherein the alkylating agent is introduced into the continuous-flow reactor as a solution, optionally pre-mixed with the solution of the cyclic tertiary amine. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je alkalno sredstvo uvedeno u reaktor s kontinuiranim protokom kao otopina, odabrano prethodno pomješan s otopinom cikličnog tercijarnog amina.
Formulation for anticorrosion paints and coatings, based on epoxy, polyurethane, acrylic, alkydic, polyester resins and mixtures thereof, and comprising a multitude of mostly bi-dimensionally developed nanoparticles, with a few hundred and about one nanometer, respectively, as to lateral dimensions and thickness, wherein said nanoparticles consist of materials containing ions available for ion exchange reactions, previously treated by ion exchange reaction with ions of long chain molecules having at least 16 carbon atoms, the rotational viscosity of the formulation at 10rpm, measured according to ASTM D4212, being lower than 55000 mPa·s 
Sastav za antikorozivne slike i premaze, stvoreno na epoksi, polieuretanskoj, akrilnoj, alkidnoj, te poliester smoli i mješavinama istih, koja se sastoji od mnoštva većinski dvodimenzionalnih nanočestica, sa par stotina laterlanih dimenzija i debljine oko jednog nanometra, navedene nanočestice sastoje se od materijala koji sadže ione slobodne za reakciju ionske izmjene, ranije tretirane sa ionskom izmjenom iona molekula dugogo lanca sa namjanje 16 ugljičnih atoma, rotacijska viskoznost formule j 10rpm, izmjereno sukladno ASTM D4212, a manja od 55000 mPa.s.
Formulation for anticorrosion paints and coatings according to claim 1 or 2, wherein the amount of said nanoparticles is lower than 2% by weight, based on the total weight of the formulation. 
Sastav antikorozivnih slika i premaza sukladno zahtjevu 1 ili 2, naznačeno time da je težinski udio navedenih nanočestica niži od 2%, uzimajući u obzir u obzir ukupnu težinu sastava
Formulation for anticorrosion paints and coatings according to claim 4 or 5 wherein said nanoparticles consist of silico-aluminate based materials. 
Sastav za antikorozivne slike i premaze sukladno zahtjevu 4 ili 5 naznačeno time da se spomenute nanočestice sastoje od materijala siliko-aluminatne baze.
Formulation for anticorrosion paints and coatings according to each of claims 5-7, wherein said long chain molecule ions are obtained by protonising amines or other compounds compatible with other formulation components. 
Sastav za antikorozivne slike i premaze sukladno zahtjevima 5-7, gdje su ioni molekula dugogo lanca dobiveni protoniranjem amina ili druih spojeva kompatibilnih sa drugim sastavnim komponentama
The insulin conjugate according to claim 1, wherein the immunoglobulin Fc region is composed of one to four domains selected from the group consisting of CH1, CH2, CH3 and CH4 domains. 
Konjugat inzulina prema patentnom zahtjevu 1, naznačen time što Fc regija imunoglobulina je sastavljen od jedne do četiri domene izabrane iz grupe koja se sastoji od CH1, CH2, CH3 i CH4 domena.
The insulin conjugate according to claim 7, wherein each domain of the immunoglobulin Fc region is a domain hybrid of a different origin derived from an immunoglobulin selected from the group consisting of IgG, IgA, IgD, IgE, and IgM. 
Konjugat inzulina prema patentnom zahtjevu 7, naznačen time što svaka domena Fc regije imunoglobulina je hibrid domena različitog porijekla izveden od imunoglobulina izabranog iz grupe koja se sastoji od IgG, IgA, IgD, IgE i IgM.
A long-acting insulin formulation having improved in vivo duration and stability, comprising the insulin conjugate of any one of claims 1 to 14. 
Formulacija inzulina sa dugotrajnim djelovanjem koja ima poboljšano in vivo trajanje i stabilnost, koja sadrži konjugat inzulina prema bilo kom od patentnih zahtjeva 1 do 14.
isolating a conjugate from the reaction mixture of (1), wherein the conjugate comprises the immunoglobulin Fc region covalently linked with the polyethylene glycol; and 
izolacije konjugata iz reakcijske smjese iz (1), pri čemu konjugat sadrži Fc regiju imunoglobulina kovalentno vezan sa polietilen glikolom; i
A conjugate according to any one of claims 1 to 14 or the formulation of claim 15 for use in a method of treating a subject having an insulin-deficiency disorder. 
Konjugat prema bilo kojem od patentnih zahtjeva 1 do 14 ili formulacija prema patentnom zahtjevu 15 za uporabu u postupku za liječenje subjekta koji ima poremećaj deficijencije inzulina .
The conjugate or formulation for use according to claim 21 wherein the insulin deficiency disorder is diabetes. 
Konjugat ili formulacija za uporabu prema patentnom zahtjevu 21 naznačeni time što, poremećaj deficijencije inzulina je dijabetes.
The PET container of claim 1 wherein the PET container has the heat induced crystallinity of about 20%, the rigid amorphous phase of about 60% and the mobile amorphous phase of about 20%. 
PET posuda iz patentnog zahtjeva 1 gdje PET posuda ima toplinom induciranu kristalnost od oko 20%, rigidnu amorfnu fazu oko 60% i mobilnu amorfnu fazu oko 20%.
The PET container of claim 1 or 2 wherein the density of the wall is greater than 1.375 g/cc, preferably about 1.385 g/cc. 
PET posuda iz patentnog zahtjeva 1 ili 2 gdje je gustoća zida veća od 1.375 g/cc, poželjno oko 1.385 g/cc.
The PET container of claim 1 wherein the moisture content of the wall is from 1780 ppm to 1980 ppm when exposed to 100% RH at 96° C. 
PET posuda iz patentnog zahtjeva 1 gdje sadržaj vlage zida je od 1780 ppm do 1980 ppm kada je izložena relativnoj vlažnosti od 100% na 96° C.
The PET container of claim 1 or 5 wherein the container is optically clear. 
PET posuda iz patentnog zahtjeva 1 ili 5 gdje je posuda optički prozirna.
The PET container of claim 1 wherein the wall, when subjected to temperature modulated differential scanning calorimetry and analyzed in the temperature range of from 0° C. to 325° C. at a heating rate of 5 °C/min, exhibits a first endothermic glass transition temperature and a second endothermic glass transition temperature higher than the first transition temperature. 
PET posuda iz patentnog zahtjeva 1 gdje zid, kada je podvrgnut temperaturom moduliranoj diferencijalnoj skenirajućoj kalorimetriji i analiziran u opsegu temperature od 0° C. do 325° C. pri brzini zagrijavanja od 5 °C/min, izlaže temperaturu prvog endotermnog prelaza stakla i temperaturu drugog endotermnog prelaza stakla višu od prve temperature prelaza.
The PET container of claim 9 wherein the second endothermic glass transition temperature is at least 30° C. higher than the first endothermic glass transition temperature. 
PET posuda iz patentnog zahtjeva 9 gdje je temperatura drugog endotermnog prelaza stakla najmanje 30° C. viša nego temperatura prvog endotermnog prelaza stakla.
The PET container of claim 10 wherein the second endothermic glass transition temperature is at least 40° C. higher than the first endothermic glass transition temperature; preferably the second endothermic glass transition temperature is at least 50° C. higher than the first endothermic glass transition temperature. 
PET posuda iz patentnog zahtjeva 10 gdje je temperatura drugog endotermnog prelaza stakla najmanje 40° C. viša nego temperatura prvog endotermnog prelaza stakla; poželjno temperatura drugog endotermnog prelaza stakla je najmanje 50° C. viša nego temperatura prvog endotermnog prelaza stakla.
The PET container of claim 13 wherein the second endothermic glass transition temperature has an enthalpy greater than 2.0. 
PET posuda iz patentnog zahtjeva 13 gdje temperatura drugog endotermnog prelaza stakla ima entalpiju veću od 2.0.
The PET container of claim 1 wherein the wall of the container has a moisture content of from about 1780 ppm to about 1980 ppm when exposed to hot-fill conditions at about 96° C. and 100% RH, and/or pasteurization conditions at 98° C., 100% RH. 
PET posuda iz patentnog zahtjeva 1 gdje zid posude ima sadržaj vlage od oko 1780 ppm do oko 1980 ppm kada je izložen uvjetima vrućeg punjenja na oko 96° C. i 100% RH, i/ili uvjetima pasterizacije na 98° C., 100% relativna vlažnost.
is independently selected from NR2; and O; 
je neovisno odabran od NR2; i O;
The compound according to claim 1, having structural formula: (AB2) or (AB2'), wherein E1, E2, E3, R4, R5, R6, R8, Ra, Q, W, X, Y, L, B, m, n have the same meaning as defined in claim 1. 
Spoj prema zahtjevu 1, naznačen time da ima strukturnu formulu: (AB2) ili (AB2'), [image] pri čemu E1, E2, E3, R4, R5, R6, R8, Ra, Q, W, X, Y, L, B, m, n imaju isto značenje kako je definirano u zahtjevu 1.
The compound according to claim 1, having structural formula: (AB4"), wherein E1, E2, E3, R4, R5, R6, R8, Ra, Q, L, B, m, n have the same meaning as defined in claim 1. 
Spoj prema zahtjevu 1, naznačen time da ima strukturnu formulu: (AB4"), [image] pri čemu E1, E2, E3, R4, R5, R6, R8, Ra, Q, L, B, m, n imaju isto značenje kako je definirano u zahtjevu 1.
*and wherein said alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N; * and wherein two or more hydrogen atoms on a carbon atom or heteroatom of said alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene, can be taken together to form a C=O, C=S, N=O, N=S, S=O or S(O)2; 
*i pri čemu navedeni alkil, alkenil, alkinil, aril, heterocikl, arilalkilen, arilalkenilen, arilalkinilen, heterociklički-alkilen, heterociklički-alkenilen ili heterociklički-alkinilen proizvoljno sadrži jedan ili više heteroatoma u skupini alkil(en), alkenil(en) ili alkinil(en), navedeni heteroatom je odabran od O, S i N; * i pri čemu dva ili više vodikovih atoma na ugljikovom atomu ili heteroatomu iz navedenog alkila, alkenila, alkinila, arila, heterocikla, arilalkilena, arilalkenilena, arilalkinilena, heterocikličkog-alkilena, heterocikličkog-alkenilena ili heterocikličkog-alkinilena, se mogu uzeti zajedno tako da tvore C=O, C=S, N=O, N=S, S=O ili S(O)2;
*and wherein R12 and R13 can be taken together in order to form a (5-, 6-, or 7-membered) heterocycle which can be unsubstituted or substituted; 
* i pri čemu R12 i R13 mogu se uzeti zajedno tako da tvore (5-, 6-, ili 7-člani) heterocikal koji može biti nesupstituiran ili supstituiran;
A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a compound according to formula (AA1) or a stereoisomer, enantiomer or tautomer thereof, wherein, 
Farmaceutski pripravak naznačen time da sadrži jednu ili više farmaceutski prihvatljivih pomoćnih tvari i terapijski učinkovitu količinu spoja prema formuli (AA1) ili njegov stereoizomer, enantiomer ili tautomer, pri čemu, [image]
each dotted line individually represents an optional double bond, wherein maximally two dotted lines selected from the five dotted lines are a double bond; 
svaka isprekidana crta pojedinačno predstavlja proizvoljnu dvostruku vezu, pri čemu najviše dvije isprekidane crte koje su odabrane od pet isprekidanih crta su dvostruka veza;
is independently selected from CR1; and N; 
je neovisno odabran od CR1; i N;
B represents a cyclic structure selected from cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; and heterocycle; 
B predstavlja cikličku strukturu odabranu od cikloalkila; cikloalkenila; cikloalkinila; arila; i heterocikla;
* and wherein said alkyl, alkenyl and alkynyl can be unsubstituted or substituted with Z; 
* i pri čemu navedeni alkil, alkenil i alkinil može biti nesupstituiran ili supstituiran sa Z;
*and wherein R12 and R13 can be taken together in order to form a (5-, 6-, or 7-membered) heterocycle which can be unsubstituted or substituted; 
* i pri čemu R12 i R13 se mogu uzeti zajedno tako da tvore (5-, 6-, ili 7-člani) heterocikal koji može biti nesupstituiran ili supstituiran;
A compound of formula (AA1) or a stereoisomer, enantiomer, tautomer, solvate, hydrate, or salt thereof for use as a medicine for the prevention or treatment of neurodegenerative disorders, wherein, 
Spoj s formulom (AA1) ili njegov stereoizomer, enantiomer, tautomer, solvat, hidrat, ili njegova sol naznačen time da je za uporabu kao lijek za sprječavanje ili liječenje neurodegenerativnih poremećaja, [image] pri čemu,
is independently selected from CR1; and N; 
E je neovisno odabran od CR1; i N;
is selected from hydrogen; alkyl; alkenyl; and alkynyl; 
R je odabran od vodika; alkila; alkenila; i alkinila;
The compound of formula (AA1) according to claim 17 for use as a medicine for the prevention or treatment of neurodegenerative disorders, wherein, 
Spoj s formulom (AA1) prema zahtjevu 17 naznačen time daje za uporabu kao lijek za sprječavanje ili liječenje neurodegenerativnih poremećaja, [image] pri čemu,